C0013162||Combination
C0248719||telmisartan
C0529793||sildenafil
C0242656||progression
C0011881||diabetic nephropathy
C0038432||streptozotocin
C0241863||diabetic
C0011881||Diabetic nephropathy
C0011881||Diabetic nephropathy
C0022661||end-stage renal disease
C0037080||signaling pathways
C0699748||pathogenesis
C0011881||Diabetic nephropathy
C0702240||elevation
C0003009||angiotensin II
C0162574||advanced glycation end products
C0162574||advanced glycation end products
C1819041||activation
C0033634||protein kinase c
C0033634||protein kinase c
C0333574||lipid accumulation
C0037080||pathways
C0242606||oxidative stress
C1171362||expression
C1704256||transforming growth factor beta-1
C1704256||transforming growth factor beta-1
C0021764||interleukins
C0007578||adhesion molecules
C3816499||pathogenic
C0242656||progression
C0011881||Diabetic nephropathy
C0008972||study
C0241863||diabetic
C0021493||intraperitoneal injection
C0038432||Streptozotocin
C0038432||Streptozotocin
C0011881||Diabetic nephropathy
C0011881||Diabetic nephropathy
C0011881||Diabetic nephropathy
C0248719||Telmisartan
C0529793||Sildenafil
C0248719||Telmisartan
C0529793||Sildenafil
C0013162||combination
C1610733||urine samples
C0033687||proteinuria
C0003062||animals
C0178913||blood
C1292533||tissue samples
C0392201||measurement of Blood glucose
C0005845||BUN
C0201976||S.Cr
C0202117||LDL
C3810607||NO
C3889969||TGF-β1
C3815172||IL-1β
C0022885||AGEPs
C0022885||SOD
C0013218||combination therapy
C0600137||BUN
C0010294||S.Cr
C0023823||LDL
C1704256||TGF-β1
C0021753||IL-1β
C0033687||Proteinuria
C0162574||AGEPs
C0038838||SOD
C0028128||NO
C0013218||combination therapy
C0011881||Diabetic nephropathy
C0013227||drugs